# Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

> **NCT05364021** · PHASE1,PHASE2 · COMPLETED · sponsor: **Longboard Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Developmental and Epileptic Encephalopathy
- Dravet Syndrome
- Lennox Gastaut Syndrome

## Interventions

- **DRUG:** LP352
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05364021
- **Lead sponsor:** Longboard Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-03
- **Primary completion:** 2023-11-16
- **Final completion:** 2023-11-20
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364021, "Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05364021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*